|
1 2 3 4 5 6 7
читать далее ... + etoposide versus topotecan gemcitabine for second-line recurrent ovarian cancer. ASCO 2006. abst.5030. 21. Scarfone G. Bolts G. et all. Phase 1 -2 seguential topotecan chemotherapy in patients with small residual disease after taxol - carboplatin as first line chemotherapy in advanced epithelial ovarian cancer. Proc. ASCO 1998: 17:362a: abst.1396. 22. Hoskins P. Eisenhauer E.et all.seguential couplets of cisplatin/topotecan and cisplatin/ paclitaxel as first- line therapy for advanced epithelial ovarian cancer: Proc. ASCO 1999:18:357a, abst.1378. 23. Gordon A. Asmar L et all. Phase 2 of seguential topotecan in combination with carboplatin followed by paclitaxel via three-hour infusion in combination with carboplatin in the treatment of newly diagnosed ovarian cancer patients with advanced disease. Proc.ASCO. 2002:21:21 За. abst.848. 24. Guppy A. Nelstrop L et all. A phase 2 study of seguential carboplatin, paclitaxel and topotecan in patients with previously untreated ovarian cancer. Pros. ASCO 2002, 21: 219a, abst.872. 25. Pfisterer J. Weber B. et all. Paclitaxel/carboplatin vs. paclitaxel/carboplatin followed by topotecan in first-line treatment of advanced ovarian cancer. Proc. ASCO 2005: 23: 456s.abst.5007. 26. Bookman M. GOG 182-ICON 5: 5-arm phase 3 randomized trial of paclitaxel and carboplatin vs combinations with gemcitabine, PEG-liposomal doxorubicin, or topotecan in patients with advanced-stage epithelial ovarian cancer or primary peritoneal carcinoma. ASCO 2006. abst 5002. 27. Gorbounova V. Tophieva S. A phase II study trial of Topotecan and Oxaliplatin in patients with advanced ovarian cancer. ASCO 2005, abst.5017 28. Markman M.: Intraperitoneal chemotherapy in the management of avarian cancer. Ann med 28: 293-296,1996. 29. Vermorken.J.В.Intraperitoneal Chemotherapy in Advanced Ovarian cancer: At last recognition. Educational lectures 17th ICACT 2006. 30. Andreopoulou. E. Et all. Phase I/ pharmacology study of intraperitoneal (IP) 3-5 day topotecan alone and with cisplatin on day 1. ASCO 2005, abst.5045 31. Gore M. Controversies in surveillance Options for patients after initial treatment for Ovarian cancer. Educan.dbokASCO 2006. pp.335-338. 32. Markman M. Uu P. et all. Phase 3 randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: J Clin Oncol 2003, 21:2460-5. 33. Robertson M. Malpass Т et all. Phase 2 study of intraperitoneal topotecan as consolidation chemotherapy in ovarian cancer. Proc.ASCO 2004:22(14s): 466, abst.5077.Источник: Хохлова С.В. Русский медицинский журнал. 2006. Т.14. №14. С.1042-1046
|
